收购人类细胞设计的积极性

• Revvity (RVTY) to acquire France-based Human Cell Design, a biotechnology company focused on human cell models for diabetes, obesity and other metabolic diseases.
• The financial terms were not disclosed and is expected to close in Q4 2026, subject to regulatory approvals and other customary closing conditions.
• The deal will add Human Cell Design's human pancreatic beta cell models to Revvity’s Life Sciences portfolio, strengthening its capabilities in drug discovery and screening for GLP-1 and other metabolic disease therapies.
• The acquired technology will also expand Revvity’s potential applications in regenerative medicine and cell-based therapies.

More on Revvity

• Revvity, Inc. 2026 Q2 - Results - Earnings Call Presentation
• Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript
• Revvity: Overvalued On Sentiment
• Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
• Revvity outlines 2026 organic growth of 4% to 5% and adjusted EPS of $5.30 to $5.40, driven by diagnostics momentum and AI-linked demand